Eric W. Refsland

发表

Quantitative Proteomics Reveals Myosin and Actin as Promising Saliva Biomarkers for Distinguishing Pre-Malignant and Malignant Oral Lesions

John V. Carlis, Robert J. Griffin, Hongwei Xie, 2010, PloS one.

Effect of analytical treatment interruption and reinitiation of antiretroviral therapy on HIV reservoirs and immunologic parameters in infected individuals

Xu G. Yu, T. Chun, J. Justement, 2018, PLoS pathogens.

Natural Polymorphisms in Human APOBEC3H and HIV-1 Vif Combine in Primary T Lymphocytes to Affect Viral G-to-A Mutation Levels and Infectivity

M. Emerman, W. Brown, C. Reilly, 2014, PLoS genetics.

The APOBEC3 family of retroelement restriction factors.

Reuben S Harris, Eric W Refsland, Eric W. Refsland, 2013, Current topics in microbiology and immunology.

APOBEC3B is an enzymatic source of mutation in breast cancer

N. A. Temiz, Jason B. Nikas, R. Harris, 2013, Nature.

Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption.

G. Learn, M. Proschan, J. Hoxie, 2016, The New England journal of medicine.

Human and Rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H Demonstrate a Conserved Capacity To Restrict Vif-Deficient HIV-1

Lela Lackey, W. Brown, R. LaRue, 2011, Journal of Virology.

Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction

W. Brown, M. Stenglein, Eric W. Refsland, 2010, Nucleic acids research.

Interactions Among DNA Ligase I, the Flap Endonuclease and Proliferating Cell Nuclear Antigen in the Expansion and Contraction of CAG Repeat Tracts in Yeast

D. M. Livingston, Eric W. Refsland, 2005, Genetics.

Highlights from the Fourth Biennial Strategies for an HIV Cure Meeting, 10–12 October 2018, Bethesda, MD, USA

Eric W Refsland, K. Salzwedel, R. Tressler, 2019, Journal of virus eradication.

Endogenous Origins of HIV-1 G-to-A Hypermutation and Restriction in the Nonpermissive T Cell Line CEM2n

R. Harris, Eric W Refsland, J. Hultquist, 2012, PLoS pathogens.

A randomized controlled safety/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infection

M. Proschan, T. Chun, J. Justement, 2017, Science Translational Medicine.

APOBEC3B is an enzymatic source of mutation in breast cancer

Jason B. Nikas, Lela Lackey, M. Carpenter, 2013, Nature.

Glycan-dependent HIV-specific neutralizing antibodies bind to cells of uninfected individuals.

J. Mascola, Eric W Refsland, A. Heredia, 2019, The Journal of clinical investigation.